Markus Stücker1. 1. Klinik für Dermatologie, Venerologie und Allergologie, Venenzentrum der Dermatologischen und Gefäßchirurgischen Kliniken, Kliniken der Ruhr-Universität Bochum, St. Maria-Hilf-Krankenhaus, Hiltroper Landwehr 11-13, 44805, Bochum, Deutschland. markus.stuecker@klinikum-bochum.de.
Abstract
BACKGROUND: Venous disorders affect a large proportion of the German population (varicose veins 13.3%, chronic venous insufficiency 40.8%). OBJECTIVES: Based on current literature, a practically oriented update on superficial venous thrombosis, varicosis, and chronic venous insufficiency is provided. RESULTS AND CONCLUSION: Superficial vein thrombosis of the legs requires comprehensive duplex ultrasonography of the superficial and deep leg veins. Only superficial vein thrombosis less than 5 cm in length and more than 3 cm from the saphenofemoral or saphenopopliteal junction can be treated conservatively with compression, cooling, and relative immobilization. Superficial vein thrombosis greater than 5 cm in length with more than 3 cm distance to the deep venous system is treated pharmacologically with fondaparinux for 45 days (approved for 30-45 days). If the surface thrombus reaches the saphenofemoral or saphenopopliteal junction at a distance of less than 3 cm, therapy analogous to deep vein thrombosis is required for 3 months. The most effective therapy for varicose veins is invasive removal. In this regard, endovenous thermal ablation has become particularly important in recent years, given that its effectiveness is of a similar order of magnitude to that of crossectomy and stripping surgery, but the complication rates are significantly lower. Invasive removal of varicose veins not only improves patients' quality of life, but also significantly reduces the risk of deep vein thrombosis. Recent epidemiological data demonstrate an increased risk of cardiovascular disease in patients with chronic venous insufficiency. There is preliminary evidence that this risk of cardiovascular disease in varicose vein patients can be lowered by varicose vein therapy.
BACKGROUND: Venous disorders affect a large proportion of the German population (varicose veins 13.3%, chronic venous insufficiency 40.8%). OBJECTIVES: Based on current literature, a practically oriented update on superficial venous thrombosis, varicosis, and chronic venous insufficiency is provided. RESULTS AND CONCLUSION: Superficial vein thrombosis of the legs requires comprehensive duplex ultrasonography of the superficial and deep leg veins. Only superficial vein thrombosis less than 5 cm in length and more than 3 cm from the saphenofemoral or saphenopopliteal junction can be treated conservatively with compression, cooling, and relative immobilization. Superficial vein thrombosis greater than 5 cm in length with more than 3 cm distance to the deep venous system is treated pharmacologically with fondaparinux for 45 days (approved for 30-45 days). If the surface thrombus reaches the saphenofemoral or saphenopopliteal junction at a distance of less than 3 cm, therapy analogous to deep vein thrombosis is required for 3 months. The most effective therapy for varicose veins is invasive removal. In this regard, endovenous thermal ablation has become particularly important in recent years, given that its effectiveness is of a similar order of magnitude to that of crossectomy and stripping surgery, but the complication rates are significantly lower. Invasive removal of varicose veins not only improves patients' quality of life, but also significantly reduces the risk of deep vein thrombosis. Recent epidemiological data demonstrate an increased risk of cardiovascular disease in patients with chronic venous insufficiency. There is preliminary evidence that this risk of cardiovascular disease in varicose vein patients can be lowered by varicose vein therapy.
Authors: Stavros K Kakkos; Manjit Gohel; Niels Baekgaard; Rupert Bauersachs; Sergi Bellmunt-Montoya; Stephen A Black; Arina J Ten Cate-Hoek; Ismail Elalamy; Florian K Enzmann; George Geroulakos; Anders Gottsäter; Beverley J Hunt; Armando Mansilha; Andrew N Nicolaides; Per Morten Sandset; Gerard Stansby; Gert J de Borst; Frederico Bastos Gonçalves; Nabil Chakfé; Robert Hinchliffe; Philippe Kolh; Igor Koncar; Jes S Lindholt; Riikka Tulamo; Christopher P Twine; Frank Vermassen; Anders Wanhainen; Marianne G De Maeseneer; Anthony J Comerota; Peter Gloviczki; Marieke J H A Kruip; Manuel Monreal; Paolo Prandoni; Melina Vega de Ceniga Journal: Eur J Vasc Endovasc Surg Date: 2020-12-15 Impact factor: 7.069
Authors: Julie Brittenden; David Cooper; Maria Dimitrova; Graham Scotland; Seonaidh C Cotton; Andrew Elders; Graeme MacLennan; Craig R Ramsay; John Norrie; Jennifer M Burr; Bruce Campbell; Paul Bachoo; Ian Chetter; Michael Gough; Jonothan Earnshaw; Tim Lees; Julian Scott; Sara A Baker; Emma Tassie; Jill Francis; Marion K Campbell Journal: N Engl J Med Date: 2019-09-05 Impact factor: 91.245
Authors: B Cosmi; M Filippini; D Tonti; G Avruscio; A Ghirarduzzi; E Bucherini; G Camporese; D Imberti; G Palareti Journal: J Thromb Haemost Date: 2012-06 Impact factor: 5.824
Authors: Marianne G De Maeseneer; Stavros K Kakkos; Thomas Aherne; Niels Baekgaard; Stephen Black; Lena Blomgren; Athanasios Giannoukas; Manjit Gohel; Rick de Graaf; Claudine Hamel-Desnos; Arkadiusz Jawien; Aleksandra Jaworucka-Kaczorowska; Christopher R Lattimer; Giovanni Mosti; Thomas Noppeney; Marie Josee van Rijn; Gerry Stansby; Philippe Kolh; Frederico Bastos Goncalves; Nabil Chakfé; Raphael Coscas; Gert J de Borst; Nuno V Dias; Robert J Hinchliffe; Igor B Koncar; Jes S Lindholt; Santi Trimarchi; Riikka Tulamo; Christopher P Twine; Frank Vermassen; Anders Wanhainen; Martin Björck; Nicos Labropoulos; Fedor Lurie; Armando Mansilha; Isaac K Nyamekye; Marta Ramirez Ortega; Jorge H Ulloa; Tomasz Urbanek; Andre M van Rij; Marc E Vuylsteke Journal: Eur J Vasc Endovasc Surg Date: 2022-01-11 Impact factor: 6.427